珍龙醒脑胶囊联合丁苯酞治疗急性脑梗死的临床研究

目的 探讨珍龙醒脑胶囊联合丁苯酞治疗急性脑梗死的临床疗效。方法 选取2018年10月—2020年12月河南科技大学第二附属医院治疗的86例急性脑梗死患者，根据随机数字法将所有患者分为对照组和治疗组，每组各43例。对照组静脉滴注丁苯酞氯化钠注射液，100 mL/次，2次/d。治疗组在对照组治疗基础上口服珍龙醒脑胶囊，2粒/次，2次/d。两组用药治疗14 d。观察两组的临床疗效和症状缓解时间，比较两组神经功能缺损程度（NIHSS）评分、同型半胱氨酸（Hcy）、N末端前脑钠肽（NT-proBNP）、D-二聚体（D-D）、超敏C反应蛋白（hs-CRP）的变化情况。结果 治疗后，治疗组总有效率是97.67%，显著高于对照组的79.07%（P＜0.05）。治疗后，治疗组出现眩晕、头痛、中枢性面瘫、肢体无力缓解时间均短于对照组（P＜0.05）。治疗后，两组NIHSS评分均较治疗前显著降低（P＜0.05）；治疗后，治疗组患者NIHSS评分低于对照组（P＜0.05）。治疗后，两组血清因子Hcy、NT-proBNP、D-D、hs-CRP水平均显著降低（P＜0.05）；治疗后，治疗组血清因子水平低于对照组（P＜0.05）。治疗组不良反应发生率是6.98%，显著低于对照组的16.28%（P＜0.05）。结论 珍龙醒脑胶囊联合丁苯酞治疗急性脑梗死具有较好的临床疗效，可明显改善患者症状，有效改善患者神经功能缺损程度，并能降低机体炎性反应，且安全有效。

Clinical study on Zhenlong Xingnao Capsules combined with butylphthalide in treatment of acute cerebral infarction

Objective To explore the clinical study of Zhenlong Xingnao Capsules combined with butylphthalide in treatment of acute cerebral infarction. Methods A total of 86 patients with acute cerebral infarction treated in the Second Affiliated Hospital of Henan University of Science and Technology from October 2018 to December 2020 were selected, and all patients were divided into control group and treatment group according to random number method, with 43 cases in each group. Patients in the control group were iv administered with Butylphthalide and Sodium Chloride Injection, 100 mL/time, twice daily. Patients in the treatment group were po administered with Zhenlong Xingnao Capsules on the basis of the control group, 2 grains/time, twice dialy. Both groups were treated for 14 d. The clinical efficacy and symptom relief time of the two groups were observed, and the changes of neurological impairment score (NIHSS), homocysteine (Hcy), N-terminal forebrain natriuretic peptide (NT-probNP), D-dimer (D-D) and hypersensitive C-reactive protein (hs-CRP) in the two groups were compared. Results After treatment, the total effective rate of treatment group was 97.67%, significantly higher than 79.07% of control group (P < 0.05). After treatment, the relief time of vertigo, headache, central facial paralysis, and limb weakness in the treatment group was shorter than that in the control group (P < 0.05). After treatment, NIHSS scores in both groups were significantly lower than those before treatment (P < 0.05). After treatment, NIHSS score in treatment group was lower than that in control group (P < 0.05). After treatment, the levels of serum factors Hcy, NT-probNP, D-D, and hs-CRP in two groups were significantly decreased (P < 0.05). After treatment, the level of serum factor in treatment group was lower than that in control group (P < 0.05). The incidence of ADR in treatment group was 6.98%, significantly lower than that in control group (16.28%) (P < 0.05). Conclusion Zhenlong Xingnao Capsules combined with butylphthalide has good clinical effect in treatment of acute cerebral infarction, and can obviously improve the symptoms of patients, effectively improve the degree of neurological impairment of patients, and can reduce the body inflammatory reaction, which is safe and effective.